Gastric Ulcer | Nexium Capsules LDA Specific Clinical Experience Investigation
Gastric Ulcer research study
What is the primary objective of this study?
The purpose of this investigation is to collect following data in patients given Nexium
capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of
gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).
Who is eligible to participate?
- Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1,
A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy).
- Patients who had been given Nexium for suppression of recurrence of gastric
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: January 1, 2013
Completed Date: March 9, 2017
Primary Outcome: Adverse events incidence
Secondary Outcome: Non-recurrence rate of peptic ulcer
Study sponsors, principal investigator, and references
Principal Investigator: Shigeru Yoshida, MD
Lead Sponsor: AstraZeneca